Octagam® 10%（一种经溶剂去污剂灭活病毒的静脉注射免疫球蛋白）的临床经验：加拿大使用情况的回顾性研究
Clinical Experience with Octagam® 10 %, a solvent detergent virus inactivated intravenous immunoglobulin: a Canadian retrospective review of utilization.
作者信息
Betschel Stephen D, Warrington Richard J, Schellenberg Robert
机构信息
St Michael's Hospital and the University of Toronto, 30 Bond St, Toronto, ON M5B 1W8 Canada.
Head, Section of Allergy & Immunology, Department of Internal Medicine, University of Manitoba, Winnipeg Health Science Center, GC319 820 Sherbrook St, Winnipeg, MB R3A 1R9 Canada.
出版信息
Allergy Asthma Clin Immunol. 2016 Jul 27;12:32. doi: 10.1186/s13223-016-0138-9. eCollection 2016.
In Canada, intravenous immune globulin (IVIg) products are licensed for six disease indications, however it has been demonstrated that patients with a number of other conditions also benefit from IVIg. Here we report the routine clinical use of Octagam(®) 10 % across three Canadian institutions. A total of 135 patients were treated with Octagam(®), for conditions represented by five distinct indication groups. The results of this review indicate that Octagam(®) has been well adopted and is prescribed to Canadian patients similar to other IVIg products. In alignment with current practices, 85 % of Octagam's utilization was classified as appropriate based on Canadian IVIg guidelines.
在加拿大，静脉注射免疫球蛋白（IVIg）产品有六种疾病适应症获得许可，然而已证明许多其他病症的患者也能从IVIg中获益。在此，我们报告Octagam(®) 10%在加拿大三个机构的常规临床应用情况。共有135例患者接受了Octagam(®)治疗，涉及五个不同适应症组所代表的病症。本综述结果表明，Octagam(®)已被广泛采用，并且与其他IVIg产品一样被开给加拿大患者。根据加拿大IVIg指南，与当前做法一致，Octagam使用的85%被归类为适当。
Zotero 插件